Vaxxinity reports fourth quarter and full-year 2023 financial results and provides corporate updates

Cape canaveral, fla., march 27, 2024 (globe newswire) -- vaxxinity, inc. (nasdaq: vaxx), a u.s. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended december 31, 2023, and provided a corporate update.
VAXX Ratings Summary
VAXX Quant Ranking